Because these organizations are newer to the healthcare landscape, they are not bound by PBM-related regulations or laws. Currently, PBMs are regulated on a state level. However, interest in regulation has increased at the federal level, including federal legislative hearings and a review of PBM business practices by the Federal Trade Commission. The ACR’s resolution asks for third-party administrators to be included in both the current regulatory framework and future oversight efforts.
The ACR considers and introduces resolutions based on its positions and policies and the work of ACR committees and the Board of Directors. The ACR’s delegation to the AMA House of Delegates consists of Gary Bryant, MD (Delegate and Delegation Chair), Eileen Moynihan, MD (Delegate), Cristina Arriens, MD (Alternate Delegate), Colin Edgerton, MD (Alternate Delegate), Luke Barré, MD (Young Physician Section representative), Christina Downey, MD (Young Physician Section representative) and Rami Diab, MD (Resident and Fellows Section representative). Input for the AMA delegation’s work on behalf of rheumatology can be directed to [email protected].
If you are experiencing specific issues with payers or have other practice concerns, the ACR offers individualized assistance to members of ACR and ARP.
